Back
Quest Diagnostics 10K Form
Sell
29
DGX
Quest Diagnostics
Last Price:
124.56
Seasonality Move:
6.17%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-02-21 | 10K | DGX/Quest Diagnostics Annual |
2022-02-28 | 10K | DGX/Quest Diagnostics Annual |
2021-02-22 | 10K | DGX/Quest Diagnostics Annual |
2020-07-24 | 10Q | DGX/Quest Diagnostics Quarterly |
2020-05-04 | 10Q | DGX/Quest Diagnostics Quarterly |
2020-02-20 | 10K | DGX/Quest Diagnostics Annual |
Receive DGX News And Ratings
See the #1 stock for the next 7 days that we like better than DGX
DGX Financial Statistics
Sales & Book Value
Annual Sales: | $9.88B |
---|---|
Cash Flow: | $340M |
Price / Cash Flow: | 16.28 |
Annual Sales: | $55.79 |
Price / Book: | 2.23 |
Profitability
EPS (TTM): | 6.87000 |
---|---|
Net Income (TTM): | $794M |
Gross Margin: | $3.43B |
Return on Equity: | 12.87% |
Return on Assets: | 6.05% |
Quest Diagnostics Earnings Forecast
Key Quest Diagnostics Financial Ratios
- The Gross Profit Margin over the past 27 years for DGX is 34.74%.
- The Selling, General & Administrative Expenses for DGX have been equal to 18.96% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 15.64% of Operating Income.
- The Net Earning history of DGX is 9.57% of Total Revenues.
- Per Share Earnings over the last 27 years have been positive in 19 years.
Quest Diagnostics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | Diagnostics & Research |
Sector: | Healthcare |
Current Symbol: | DGX |
CUSIP: | 74834L |
Website: | questdiagnostics.com |
Debt
Debt-to-Equity Ratio: | 0.69 |
---|---|
Current Ratio: | 0.92 |
Quick Ratio: | 0.73 |
Price-to-Earnings
Trailing P/E Ratio: | 15.6 |
---|---|
Forward P/E Ratio: | 13.6 |
DGX Technical Analysis vs Fundamental Analysis
Sell
29
Quest Diagnostics (DGX)
is a Sell
Is Quest Diagnostics a Buy or a Sell?
-
Quest Diagnostics stock is rated a Sell
The current Quest Diagnostics [DGX] share price is $124.30. The Score for DGX is 29, which is 42% below its historic median score of 50, and infers higher risk than normal.